Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
93% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. ROSG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ROSG' s Cash to Debt Range Over the Past 10 Years
Min: 0.77  Med: 726.72 Max: No Debt
Current: No Debt
Equity to Asset 0.82
ROSG's Equity to Asset is ranked higher than
84% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. ROSG: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
ROSG' s Equity to Asset Range Over the Past 10 Years
Min: -0.27  Med: 0.69 Max: 0.88
Current: 0.82
-0.27
0.88
Z-Score: -8.47
WACC vs ROIC
4.25%
-215.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -151.10
ROSG's Operating margin (%) is ranked lower than
76% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. ROSG: -151.10 )
Ranked among companies with meaningful Operating margin (%) only.
ROSG' s Operating margin (%) Range Over the Past 10 Years
Min: -9864.67  Med: -4112.94 Max: -151.1
Current: -151.1
-9864.67
-151.1
Net-margin (%) -166.01
ROSG's Net-margin (%) is ranked lower than
77% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.52 vs. ROSG: -166.01 )
Ranked among companies with meaningful Net-margin (%) only.
ROSG' s Net-margin (%) Range Over the Past 10 Years
Min: -11003.33  Med: -5202.49 Max: -166.01
Current: -166.01
-11003.33
-166.01
ROE (%) -120.90
ROSG's ROE (%) is ranked lower than
85% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. ROSG: -120.90 )
Ranked among companies with meaningful ROE (%) only.
ROSG' s ROE (%) Range Over the Past 10 Years
Min: -545.27  Med: -84.49 Max: -47.3
Current: -120.9
-545.27
-47.3
ROA (%) -103.26
ROSG's ROA (%) is ranked lower than
87% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ROSG: -103.26 )
Ranked among companies with meaningful ROA (%) only.
ROSG' s ROA (%) Range Over the Past 10 Years
Min: -240.7  Med: -78.2 Max: -40.87
Current: -103.26
-240.7
-40.87
ROC (Joel Greenblatt) (%) -245.03
ROSG's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. ROSG: -245.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ROSG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1452.9  Med: -1046.33 Max: -202.49
Current: -245.03
-1452.9
-202.49
Revenue Growth (3Y)(%) 130.10
ROSG's Revenue Growth (3Y)(%) is ranked higher than
97% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. ROSG: 130.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ROSG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 130.1
Current: 130.1
0
130.1
EBITDA Growth (3Y)(%) -15.20
ROSG's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ROSG: -15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ROSG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.6  Med: -29.7 Max: -4.6
Current: -15.2
-69.6
-4.6
EPS Growth (3Y)(%) -21.70
ROSG's EPS Growth (3Y)(%) is ranked lower than
77% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ROSG: -21.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ROSG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.9  Med: -30.4 Max: 3.5
Current: -21.7
-68.9
3.5
» ROSG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

ROSG Guru Trades in

ROSG Guru Trades in

Q3 2014

ROSG Guru Trades in Q3 2014

Jim Simons 18,400 sh (New)
» More
Q4 2014

ROSG Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:VRTT, NAS:NSPH, NAS:CHEK, NAS:GENE, NAS:DRIO, NAS:WGBS, NAS:HTGM, OTCPK:SYGWF, OTCPK:MHTX, NAS:CAPN, NAS:TEAR, NAS:ROKA, NAS:BIOC, OTCPK:CBIS, NAS:APPY, OTCPK:MDIT, OTCPK:LEDIF, NAS:BASI, OTCBB:RPBIF, OTCPK:GNWSF » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.

Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Ratios

vs
industry
vs
history
P/B 1.36
ROSG's P/B is ranked higher than
85% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.49 vs. ROSG: 1.36 )
Ranked among companies with meaningful P/B only.
ROSG' s P/B Range Over the Past 10 Years
Min: 0.48  Med: 2.4 Max: 37.02
Current: 1.36
0.48
37.02
P/S 1.52
ROSG's P/S is ranked higher than
75% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. ROSG: 1.52 )
Ranked among companies with meaningful P/S only.
ROSG' s P/S Range Over the Past 10 Years
Min: 1.42  Med: 30.3 Max: 200.29
Current: 1.52
1.42
200.29
Current Ratio 4.73
ROSG's Current Ratio is ranked higher than
78% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. ROSG: 4.73 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.91 Max: 26.26
Current: 4.73
1.14
26.26
Quick Ratio 4.73
ROSG's Quick Ratio is ranked higher than
82% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ROSG: 4.73 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.91 Max: 26.26
Current: 4.73
1.14
26.26
Days Sales Outstanding 108.36
ROSG's Days Sales Outstanding is ranked lower than
79% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. ROSG: 108.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.98  Med: 159.8 Max: 885.73
Current: 108.36
38.98
885.73
Days Payable 62.81
ROSG's Days Payable is ranked higher than
53% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.91 vs. ROSG: 62.81 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 62.27  Med: 657.9 Max: 1066.71
Current: 62.81
62.27
1066.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -31.10
ROSG's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. ROSG: -31.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ROSG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -236  Med: -68.2 Max: -6.3
Current: -31.1
-236
-6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.46
ROSG's Price/Net Cash is ranked higher than
91% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.65 vs. ROSG: 2.46 )
Ranked among companies with meaningful Price/Net Cash only.
ROSG' s Price/Net Cash Range Over the Past 10 Years
Min: 1.31  Med: 4.2 Max: 37.67
Current: 2.46
1.31
37.67
Price/Net Current Asset Value 1.63
ROSG's Price/Net Current Asset Value is ranked higher than
92% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.23 vs. ROSG: 1.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ROSG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.14  Med: 3.1 Max: 9.53
Current: 1.63
1.14
9.53
Price/Tangible Book 1.33
ROSG's Price/Tangible Book is ranked higher than
89% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.63 vs. ROSG: 1.33 )
Ranked among companies with meaningful Price/Tangible Book only.
ROSG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 2.6 Max: 26.84
Current: 1.33
0.88
26.84
Price/Median PS Value 0.05
ROSG's Price/Median PS Value is ranked higher than
96% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. ROSG: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
ROSG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 1.09 Max: 6.21
Current: 0.05
0.05
6.21
Earnings Yield (Greenblatt) (%) -188.62
ROSG's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. ROSG: -188.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ROSG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -195.82  Med: 182.9 Max: 691
Current: -188.62
-195.82
691

More Statistics

Revenue (TTM) (Mil) $10.55
EPS (TTM) $ -1.05
Beta0.33
Short Percentage of Float3.10%
52-Week Range $0.71 - 3.10
Shares Outstanding (Mil)20.85

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 13 19 26
EPS ($) -0.73 -0.55 -0.37
EPS w/o NRI ($) -0.73 -0.55 -0.37
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for... Aug 24 2016
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for... Aug 24 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera... Aug 04 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera... Aug 04 2016
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health... Aug 02 2016
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment Jul 11 2016
Rosetta Genomics Gets Patent Allowance For microRNA-based Ovarian Cancer Treatment Jul 11 2016
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment Jul 11 2016
Rosetta Genomics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 06 2016
Rosetta Genomics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 06 2016
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of... Jun 23 2016
Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 Jun 22 2016
Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays Jun 21 2016
Here’s Why These Five Stocks Are Gaining Ground on Tuesday Jun 21 2016
Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays Jun 21 2016
Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid... May 26 2016
Rosetta Genomics Receives Approval from New York State for Four PCR-based Assays May 23 2016
Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays May 23 2016
Edited Transcript of ROSG earnings conference call or presentation 19-May-16 2:00pm GMT May 19 2016
Rosetta Genomics Reports 2016 First Quarter Results May 19 2016
Rosetta Genomics Reports 2016 First Quarter Financial Results May 19 2016
Rosetta Genomics to Host 2016 First Quarter Financial and Business Update Conference Call on May 19,... May 16 2016
Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on... May 16 2016
Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 13 2016
Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: 2015 By the Numbers Apr 13 2016
ROSETTA GENOMICS LTD. Financials Mar 29 2016
ROSG: Revenue Growth Accelerated in 4Q15 Mar 28 2016
Rosetta Genomics Reports 2015 Full Year Financial Results Mar 23 2016
Rosetta Genomics Reports 2015 Full Year Financial Results Mar 23 2016
Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on... Mar 17 2016
Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development Feb 29 2016
Rosetta Genomics Announces Agreement with America’s Choice Provider Network for Entire Suite of... Feb 01 2016
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for... Jan 25 2016
Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of... Jan 11 2016
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the... Jan 06 2016
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics to Present at the LD Micro Main Event Dec 09 2015
Rosetta Genomics Reports Third Quarter 2015 Financial Results Dec 09 2015
Rosetta Genomics Reports Financial Results for the First Half of 2015 Oct 27 2015
Positive Performance Data from Validation Study of Rosetta Genomics’ microRNA-based Diagnostic... Oct 21 2015
Rosetta Genomics to Host Business Update and Six Month Financials Conference Call on October 27,... Oct 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)